- Home
- PHVS vs COLL Comparison
PHVS vs COLL Comparison
Compare PHVS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- COLL
- Stock Information
- Founded
- PHVS 2015
- COLL 2002
- Country
- PHVS Switzerland
- COLL United States
- Employees
- PHVS N/A
- COLL N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- COLL Health Care
- Exchange
- PHVS Nasdaq
- COLL Nasdaq
- Market Cap
- PHVS 980.9M
- COLL 958.8M
- IPO Year
- PHVS 2021
- COLL 2015
- Fundamental
- Price
- PHVS $22.32
- COLL $32.52
- Analyst Decision
- PHVS Buy
- COLL Strong Buy
- Analyst Count
- PHVS 6
- COLL 4
- Target Price
- PHVS $37.17
- COLL $43.75
- AVG Volume (30 Days)
- PHVS 33.8K
- COLL 310.3K
- Earning Date
- PHVS 08-13-2025
- COLL 08-07-2025
- Dividend Yield
- PHVS N/A
- COLL N/A
- EPS Growth
- PHVS N/A
- COLL N/A
- EPS
- PHVS N/A
- COLL 1.25
- Revenue
- PHVS N/A
- COLL $664,283,000.00
- Revenue This Year
- PHVS N/A
- COLL $20.23
- Revenue Next Year
- PHVS N/A
- COLL $3.82
- P/E Ratio
- PHVS N/A
- COLL $25.92
- Revenue Growth
- PHVS N/A
- COLL 17.17
- 52 Week Low
- PHVS $11.51
- COLL $23.23
- 52 Week High
- PHVS $25.76
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- PHVS 73.31
- COLL 69.85
- Support Level
- PHVS $17.63
- COLL $30.60
- Resistance Level
- PHVS $19.00
- COLL $33.22
- Average True Range (ATR)
- PHVS 1.20
- COLL 0.85
- MACD
- PHVS 0.35
- COLL 0.27
- Stochastic Oscillator
- PHVS 92.15
- COLL 82.32
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.